In April, Boston Scientific (BSX) closed two acquisitions: NxThera and nVision Medical. The NxThera closing was on April 30. NxThera developed the Rezūm System, which is a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (or BPH).
Boston Scientific already had a minority stake in NxThera. The acquisition involved an upfront payment of $306 million and potential commercial milestone payments up to $100 million over a period of four years. NxThera will be integrated into Boston Scientific’s urology and pelvic health business.
On April 16, Boston Scientific acquired nVision Medical, a private company with a focus on women’s health. It developed the first and only device that has received approval from the FDA for collecting cells from fallopian tubes and offering a potential platform for early diagnosis of ovarian cancer. The acquisition involved an upfront payment of $150 million and additional potential clinical and commercial milestones of $125 million over a period of four years. Boston Scientific will integrate nVision into its urology and pelvic health business.
At the end of the first quarter, the maximum amount of future contingent consideration that Boston Scientific could be required to pay was ~$1.3 billion. That includes $105 million in research and development and commercialization-based milestones and $48 million in revenue-based payments.
In the next part of this series, we’ll take a look at Boston Scientific’s strategic investment in Millipede and its geographic performance.